A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
NCT ID: NCT01470118
Last Updated: 2013-02-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
127 participants
INTERVENTIONAL
2011-10-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
NCT01732757
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
NCT01363700
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
NCT00534794
Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis
NCT01657240
Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis
NCT00241319
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LASTACAFT® (alcaftadine 0.25%)
One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
alcaftadine 0.25% ophthalmic solution
One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
Pataday™ (olopatadine 0.2%)
One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
olopatadine 0.2% ophthalmic solution
One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)
One drop of placebo instilled in each eye at Day 0 and Day 14.
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
One drop of placebo instilled in each eye at Day 0 and Day 14.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alcaftadine 0.25% ophthalmic solution
One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
olopatadine 0.2% ophthalmic solution
One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
One drop of placebo instilled in each eye at Day 0 and Day 14.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to not wear contact lenses at least 72 hours prior to the study start and during the study period
Exclusion Criteria
* Eye surgery within 3 months or vision correction surgery within 6 months
* Any planned surgery during the study or 30 days after the study
10 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McLaurin EB, Marsico NP, Ackerman SL, Ciolino JB, Williams JM, Villanueva L, Hollander DA. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther. 2014 Oct;31(10):1059-71. doi: 10.1007/s12325-014-0155-3. Epub 2014 Sep 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GMA-LAS-011-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.